Literature DB >> 22577210

The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients.

Janet Lo1, Jorge Plutzky.   

Abstract

Complications of atherosclerosis, including myocardial infarction and stroke, are the leading cause of death and disability worldwide. Recent data strongly implicate cardiovascular death as a contributor to mortality among patients with human immunodeficiency virus (HIV) infection, with evidence suggesting increased incidence of atherosclerosis among these patients. Therefore, greater understanding of atherosclerotic mechanisms and how these responses may be similar or distinct in HIV-infected patients is needed. Key concepts in atherosclerosis are reviewed, including the evidence that inflammation and abnormal metabolism are major drivers of atherosclerosis, and connected to the current literature regarding atherosclerosis in the context of HIV.

Entities:  

Mesh:

Year:  2012        PMID: 22577210      PMCID: PMC3349296          DOI: 10.1093/infdis/jis201

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes.

Authors:  I W Park; J F Wang; J E Groopman
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

2.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.

Authors:  Tricia H Burdo; Janet Lo; Suhny Abbara; Jeffrey Wei; Michelle E DeLelys; Fred Preffer; Eric S Rosenberg; Kenneth C Williams; Steven Grinspoon
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

3.  Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.

Authors:  Kristina Koppel; Göran Bratt; Sam Schulman; Håkan Bylund; Eric Sandström
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

4.  Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.

Authors:  Katja Wolf; Dimitrios A Tsakiris; Rainer Weber; Peter Erb; Manuel Battegay
Journal:  J Infect Dis       Date:  2002-01-18       Impact factor: 5.226

5.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.

Authors:  Kathrin S Michelsen; Michelle H Wong; Prediman K Shah; Wenxuan Zhang; Juliana Yano; Terence M Doherty; Shizuo Akira; Tripathi B Rajavashisth; Moshe Arditi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries.

Authors:  Ramesh Paladugu; Weiping Fu; Brian S Conklin; Peter H Lin; Alan B Lumsden; Qizhi Yao; Changyi Chen
Journal:  J Vasc Surg       Date:  2003-09       Impact factor: 4.268

7.  Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients.

Authors:  A Tabib; C Leroux; J F Mornex; R Loire
Journal:  Coron Artery Dis       Date:  2000-02       Impact factor: 1.439

Review 8.  Inflammation and plaque vulnerability.

Authors:  Prediman K Shah
Journal:  Cardiovasc Drugs Ther       Date:  2008-10-24       Impact factor: 3.727

9.  HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.

Authors:  James Dressman; Jeanie Kincer; Sergey V Matveev; Ling Guo; Richard N Greenberg; Theresa Guerin; David Meade; Xiang-An Li; Weifei Zhu; Annette Uittenbogaard; Melinda E Wilson; Eric J Smart
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

10.  Combination antiretroviral therapy and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

View more
  27 in total

Review 1.  Inflammation, immune activation, and cardiovascular disease in HIV.

Authors:  Eric Nou; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

2.  Novel mediators of statin effects on plaque in HIV: a proteomics approach.

Authors:  Chris deFilippi; Janet Lo; Robert Christenson; Ida Grundberg; Lauren Stone; Markella V Zanni; Hang Lee; Steven K Grinspoon
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.177

Review 3.  HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research.

Authors:  Gerald S Bloomfield; Prateeti Khazanie; Alison Morris; Cristina Rabadán-Diehl; Laura A Benjamin; David Murdoch; Virginia S Radcliff; Eric J Velazquez; Charles Hicks
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

Review 4.  Cardiovascular disease and HIV infection.

Authors:  Virginia A Triant
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

5.  Anti-Inflammatory Interleukin 10 Inversely Relates to Coronary Atherosclerosis in Persons With Human Immunodeficiency Virus.

Authors:  Lindsay T Fourman; Charles F Saylor; Lediya Cheru; Kathleen Fitch; Sara Looby; Kiana Keller; Jake A Robinson; Udo Hoffmann; Michael T Lu; Tricia Burdo; Janet Lo
Journal:  J Infect Dis       Date:  2020-02-03       Impact factor: 5.226

6.  Recurrence after hospitalization for acute coronary syndrome among HIV-infected and HIV-uninfected individuals.

Authors:  J L Marcus; L B Hurley; A Prasad; J Zaroff; D B Klein; M A Horberg; A S Go; G N DeLorenze; C P Quesenberry; S Sidney; J C Lo; M J Silverberg
Journal:  HIV Med       Date:  2018-09-04       Impact factor: 3.180

Review 7.  Cardiovascular Disease, Statins, and HIV.

Authors:  Allison Ross Eckard; Eric G Meissner; Inderjit Singh; Grace A McComsey
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

8.  Atherosclerosis is Evident in Treated HIV-Infected Subjects With Low Cardiovascular Risk by Carotid Cardiovascular Magnetic Resonance.

Authors:  Kathleen A M Rose; Jaime H Vera; Peter Drivas; Winston Banya; Niall Keenan; Dudley J Pennell; Alan Winston
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

9.  Associations between antiretroviral use and subclinical coronary atherosclerosis.

Authors:  Guajira P Thomas; Xiuhong Li; Wendy S Post; Lisa P Jacobson; Mallory D Witt; Todd T Brown; Lawrence A Kingsley; John P Phair; Frank J Palella
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

10.  Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS production.

Authors:  Lynn Pulliam; Cyrus Calosing; Bing Sun; Carl Grunfeld; Hans Rempel
Journal:  J Interferon Cytokine Res       Date:  2014-04-14       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.